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Altered metabolites level in the biosystems, is the potential cause of cancer, the primary reason of alteration 
of metabolism is change in nutrient consumption and waste excretion, as a result genetic mutation leads 
to cancer initiation and progression. Aberration of specific metabolites such as fumarate, succinate, 
2-hydroxyglutarate may alter cell signaling. We collected liver and kidney samples and prepared for 1H 
NMR analysis, then executed NMR spectroscopy. We used a set of domestic R scripts to perform an 
unsupervised principal component analysis (PCA) and a supervised orthogonal signal correction partial 
least-squares discriminant analysis (OSC-PLS-DA). It signifies class discrimination for getting a clear 
separation, whereas PCA scores plot signifies the model group kept further away from the control group 
than drug group on the horizontal axis. In another PCA scores plots, most parts of the control group was 
overlapping with the drug group but was distant from the model group. Marsdenia tenacissima extract 
(MTE) (Chines name: Xiao-Ai-Ping, XAP) modulates level of crucial metabolites such as fumarate, 
lactate, succinate, determined by 1H NMR spectroscopy and their altered level contributes major role 
in cancer.
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INTRODUCTION
MTE is an anti-cancer, traditional Chinese herbal 
medicine. It has been widely used in various diseases 
and also in cancer, for many decades. But previously, 
no metabolomics study is carried out on MTE. In this 
research study, we explored the anticancer action of 
MTE in order to metabolomics approach, that how the 
level of some metabolites directly or indirectly involved 
with progression and suppression of cancer, modulated 
by MTE.
Metabolomics is a kind of newly emerging subject 
in recent decades which focuses on the changes of all 
the metabolites produced by external stimulus in the 
biosystem. This process is used to track the biomarkers 
according to the changes of the metabolic fingerprint 
and illuminate the overall effect (Roy et al., 2017), now 
metabolomics methods have been widely employed in 
recent years (Griffin, 2004; Lou et al., 2015). We unveiled 
in this research study, that some crucial metabolites play 
a major role in cancer. Mainly, the overexpression of 
succinate (Selak et al., 2005) and lactate (Hirschhaeuser, 
Sattler, Mueller-Klieser, 2011) links with cancer 
formation. The aim of this research was to investigate the 
curative effect of MTE on MDA-MB-231 in nude mice at 
the dosage of 2.5g/kg, using an NMR based metabolomics 
approach complemented with the histological inspection.
MATERIAL AND METHOD 
Sample collection and preparation for 1H NMR 
analysis 
After three weeks of the treatment, all mice fasted 
overnight. The next day after the final administration 
of MTE and after anesthetization by chloral hydrate 
(350 mg kg-1, i.p.) all of them were sacrificed. Their 
D. Roy, C. Chen, J.-s. Wang, S. Yuan, L. Sun
Braz. J. Pharm. Sci. 2018;54(2):e17604Page 2 / 8
livers and kidneys were harvested and frozen in the liquid 
nitrogen and stored at -80 ℃ immediately. Before 1H NMR 
analysis, frozen mice liver and kidney tissues were weighted 
(500 mg) and homogenized in 50% acetonitrile/H2O (3 mL) 
and centrifuged at 12000 rpm for 10 min at 4 °C. We 
collected the supernatant. And then, the supernatant was 
lyophilized and reconstituted in 550 μL D2O in phosphate-
buffered solution (0.2 M Na2HPO4 –NaH2PO4, pH 7.4). 
We used TSP (0.05 wt%) as an internal standard for D2O. 
The supernatant was transferred into a 5 mm NMR tube 
for 1H NMR analysis after the solution was vortexed and 
centrifuged at 12000 rpm for 10 min to remove any debris. 
D2O was used for field frequency locking and TSP was used 
as a chemical shift reference (1H, 0.00 ppm).
1H NMR spectroscopy 
All the 1H NMR spectra of liver and kidney samples 
were acquired at 298 K on a Bruker Avance 500 MHz 
flow-injection spectrometer (Bruker GmbH, Karlsruhe, 
Germany) with a Bruker 5 mm probe, using a modified 
transverse relaxationedited Call-Purcell-Meiboom-Gill 
(CPMG) sequence (90(τ–180- τ) n-acquisition) with a total 
spin-echo delay (2nτ) of 10 ms to suppress the signals of 
proteins, with 128 transients collected into 32 768 (32 K) 
data points, a spectral width of 10 000 Hz, an acquisition 
time of 3.27 s. The spectra were Fourier transformed after 
multiplying the FIDs by an exponential weighting function 
corresponding to a line-broadening of 0.5 Hz. 
Data pre-processing and peak assignments
The 1H NMR spectra were phased and baseline-
corrected manually using Bruker Topspin 3.0 software 
(Bruker GmbH, Karlsruhe, Germany). The spectra were 
converted to ASCII-format files by using MestReNova 
(Version 8.0.1, Mestrelab Research SL) and then imported 
into “R” (http://cran.r-project.org/) for multivariate data 
analysis using internally developed R scripts. The spectra 
were split into 0.015 ppm average integrated spectral 
regions (buckets) between 0.2 and 10 ppm. Then, the 
data were probability quotient-normalized to account for 
variation in sample dilutions. We assigned the metabolites 
in the NMR spectra according to the previous literature 
and queried performed in open access databases, such as 
the Madison metabolomics consortium database (http://
mmcd.nmrfam.wisc.edu/) and the human metabolome 
database (http://www.hmdb.ca/). We also used Chenomx 
NMR suite 7.7 software and the statistical total correlation 
spectroscopy (STOCSY) technique to assign the 
metabolites.
Data analysis
We used a set of domestic R scripts to perform 
an unsupervised PCA and a supervised OSC-PLS-DA. 
PCA was performed to show a general overview of the 
metabolic pattern through using the NMR data and then, 
OSC-PLS-DA was performed to show differences in 
metabolic alterations across the liver and kidney tissues. 
Each OSC-PLS-DA model was confirmed by repeated 
two-fold cross-validation, as follows: the validity of the 
model against overfitting was assessed using the parameter 
R2Y, and the predictive ability was described by Q2.
Color-coded loading and S-plots were constructed 
to illustrate the variables that contributed to the grouping. 
The fold changes and the associated p-values adjusted 
by BH (Benjamini–Hochberg) methods of different 
metabolites in liver and kidney samples were calculated 
and listed in Table I (for liver samples) and Table II (for 
kidney samples).
RESULTS AND DISCUSSION
Multivariate analysis of 1H NMR spectra 
We used the supervised OSC-PLS-DA to remove 
variations that were unrelated to class discrimination for 
getting a clear separation. In the PCA scores plots of the 
liver (Figure 1A), the model group kept further away from 
the control group than drug group on the horizontal axis. 
In another PCA scores plots (Figure 1B for kidney), most 
parts of the control group were overlapping with the drug 
group but were distant from the model group. 
The loading plot (Figure 1B, C, E, F) was constructed 
by a covariance-based pseudo-spectrum and it was used to 
show color-coded according to the absolute values of the 
correlation coefficients (r2). The weight of a variable in the 
discrimination model was determined by calculating the 
square of its r2 and ranged from zero (blue areas) to high 
values (red areas). Changes in metabolites were directly 
visualized as fold-changes in these plots (Figure 2). They 
are color-coded according to the p-values of differences 
among the groups. 
In this study, we also analyzed the antitumor 
activity of MTE with 1H NMR-based metabolomics 
approach. OPLS-DA analysis of NMR data from livers 
and kidneys revealed that MTE induced severe metabolic 
perturbations (Figure 3). Both of the livers and kidneys’ 
model groups were found with the significant higher level 
of succinate. It can be catalyzed into fumarate by succinate 
dehydrogenase (SDH). SDH is also a tumor suppressor. 
The succinate accumulated in the mitochondria due to 
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SDH inhibition is transported to the cytosol. Elevated 
cytosolic succinate inhibits HIF-prolyl hydroxylase 
(PHD) and thereby Hypoxia-inducible factor-α (HIF-α) 
hydroxylation. HIF-α makes up HIF combined with HIF-β. 
In many tumors, oxygen availability becomes limited 
(hypoxia) very quickly during cancer development. 
Intermittent hypoxia may paradoxically be the only 
reason for increased tumor glycolysis (Zu, Guppy, 2004). 
The major regulator of the response to hypoxia is the 
HIF transcription factor, forcefully, emphasizing the 
importance of HIF in tumor development or sustention. In 
addition, it was demonstrated that HIF activation resulting 
from von Hippel-Lindau (VHL) mutations promotes 
metastasis by inducing the expression of met and CXR4 
(Selak et al., 2005). The VHL gene product (pVHL) is 
part of an E3 ubiquitin ligase complex that binds to the 
oxygen-dependent degradation (ODD) domain of HIF-α in 
an oxygen-dependent manner and targets it for degradation 
(Pugh, Ratcliffe, 2003; Semenza, 2002). Consequently, 
pVHL binding to HIF-α is decreased, and elevated 
HIF activity induces expression of genes that facilitate 
angiogenesis, metastasis, and metabolism, leading to 
TABLE I - Identified metabolites in the livers from different groups with log2(FC) and p-values a Multiplicity: singlet (s), doublet 
(d), triplet (t), quartets (q), multiplets (m). b Color coded according to the log2(FC), red represents increased and blue represents 
decreased concentrations in glyphosate exposed groups. Color bar c p-values corrected by BH (Benjamini 
Hochberg) methods were calculated based on a parametric Student’s t-test or a nonparametric Mann–Whitney test (dependent on 
the conformity to normal distribution). *p < 0.05, **p < 0.01, ***p < 0.001
Metabolites Chemical shift (ppm)a
C vs. M C vs. H
log2(FC)b Pc log2(FC) P
Valine 1.05(d) -0.15 0.09
Isoleucine 1.00(t) -0.16 0.14
Leucine 0.95(t) -0.01 0.19 *
3-Hydroxybutyrate 1.21(d) -0.02 -0.52 *
Lactate 1.33(d),4.12(t) 0.02 -0.39 **
Alanine 1.49(d) 0.11 0.06
Acetate 1.93(d) 0.14 0.28 *
Glutamate 2.08(m),2.35(m) 0.19 * 0.25 ***
Succinate 2.41(s) 1.19 ** 0.45
Carnitine 2.47(m) -0.45 * -0.08
Methionine 2.66(q) 0.14 0.29 **
Creatine 3.04(s) 0.23 0.37 **
Ethanolamine 3.14(t) 0.39 0.18
Choline 3.21(s) -0.05 0.01
Taurine 3.28(t),3.42(m) -0.04 0.04
myo-Inositol 3.62(m),4.07(q) 0.22 ** 0.17 **
Betaine 3.92(s) -0.24 -0.20
Glucose 3.80(m),5.24(d) -0.18 * -0.18 **
Uracil 5.81(d),7.55(d) 0.07 -0.23 *
Inosine 6.11(d),8.36(s) 0.24 0.29 *
Fumarate 6.53(s) 0.14 -0.02
Tyrosine 6.91(d),7.20(d) -0.05 -0.10
Niacinamide 7.60(q),8.72(q),8.95(d) 0.09 -0.01
Theophylline 8.01(s) -0.11 0.02
ATP 8.51(s) 0.36 -0.08
AMP 8.59(s) 0.07 -0.01
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more aggressive tumors (Selak et al., 2005). To sum up, 
succinate may function as an intracellular messenger 
between mitochondria and the cytosol and has a profound 
effect on cytosolic enzymes (PHD) and consequently on 
nuclear events (gene expression by HIF) (Figure 4).
Significant alteration level of metabolites with their 
related expression and relevant action are summarized 
in the Table III. All the above indicates that the float of 
TABLE II - Identified metabolites in the kidney from different groups with log2(FC) and p-values a Multiplicity: singlet (s), doublet 
(d), triplet (t), quartets (q), multiplets (m). b Color coded according to the log2(FC), red represents increased and blue represents 
decreased concentrations in glyphosate exposed groups. Color bar c p-values corrected by BH (Benjamini 
Hochberg) methods were calculated based on a parametric Student’s t-test or a nonparametric Mann–Whitney test (dependent on 
the conformity to normal distribution). *p < 0.05, **p < 0.01, ***p < 0.001
Metabolites Chemical shift (ppm)a
C VS. M C vs. H
log2(FC)b Pc log2(FC) P
Valine 1.00(d), 1.05(d) -0.33 0.21
Isoleucine 0.94(d), 1.02(d) -0.20 0.09
Leucine 0.97(t), 1.68(m) -0.28 0.10
3-Hydroxybutyrate 1.20(d) -0.29  -0.13
Lactate 1.34(d), 4.12(q) 0.00 -0.02
Alanine 1.49(d) 0.54 * 0.40
Acetate 1.93(s) 0.11 0.34
Succinate 2.41(s) 1.31 ** 0.84 *
Lysine 1.73(q), 1.90(q), 3.03(s) -0.36 0.04
Creatine 3.04(d) -0.05 -0.12
Glutamine 2.13(t), 2.46(q) 0.17 0.28
Glucose 3.25(d), 3.50(m), 3.80(m), 4.66(d), 5.24(d) -0.06 -0.02
Taurine 3.27(t) -0.20 0.01
Glutamate 2.34(m), 2.05(t) 0.99 ** 0.74 ***
Glutathione 2.18(t), 2.56(m), 2.95(m) 0.51 * 0.73 *
Glycine 2.57(s) -0.05 0.33
Lactose 4.46(s) -1.5 ** -0.22
3-Hydromuconate 5.63(m) 0.58 0.33
Histamine 3.00(t), 7.12(s), 7.96(s) 0.15 0.19
sn-Glycero-3-phosphocholine 3.23(s) 0.29 0.43
Niacinamide 7.60(q), 8.72(d), 8.94(d) -0.37 * -0.34 *
Inosine 4.44(d), 6.11(d), 8.24(s), 8.36(s) -0.82 ** -0.30 *
Maltose 3.64(m), 3.31(s) -0.90 ** -0.38
Fumarate 6.53(s) 0.48 1.05 *
Tyrosine 6.90(d), 7.19(d) -0.37 -0.29
Phenylalanine 7.38(m) -0.19 -0.12
Formate 8.46(s) -0.05 0.20
Xanthine 7.92(s) 0.39 0.16
Uridine 5.91(q), 7.88(s), 7.90(s) 1.12 ** -0.64
ATP 6.14(d), 8.27(s), 8.51(s) -0.22 -0.03
AMP 8.59(s) 0.06 0.15
3-Hydroxyphenylacetate 6.81(s) -0.23 -0.45
Uracil 5.81(d), 7.55(d) -0.48 -0.50
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FIGURE 1 - OPLS-DA analysis of liver and kidney extract 1H NMR data of control, model, and MTE groups. Score plots (A 
for liver, D for kidney) and the corresponding loading plots of OPLS-DA (B and C for liver, E, and F for kidney) color-coded 
with the absolute value of correlation coefficients. The color bar corresponds to the weight of the corresponding variable in the 
discrimination of statistically significant (red) or non-significant (blue).Positive and negative peaks indicate a relatively decreased 
and increased metabolite level. 
FIGURE 2 - Typical 500 MHz 1H NMR spectra of liver tissue and kidney extracts obtained from Con. (black lines), MTE 
(XAP) (green lines) and Mod groups (red lines). The metabolites are labeled as follows: 1. Valine, 2. Isoleucine, 3. Leucine, 4. 
3-Hydroxybutyrate, 5. Lactate, 6. Alanine, 7. Acetate, 8. Succinate, 9. Lysine, 10. Creatine, 11. Glutamine, 12. Glucose, 13. Taurine, 
14. Glutamate, 15. Glutathione, 16. Glycine, 17. Lactose, 18. 3-Hydromuconate, 19. Histamine, 20. sn-Glycero-3-phosphocholine, 
21. Niacinamide, 22. Inosine, 23. Maltose, 24. Fumarate, 25. Tyrosine, 26. Phenylalanine, 27. Formate, 28. Xanthine, 29. Uridine, 
30. ATP, 31. AMP, 32. 3-Hydroxyphenylacetate, 33. Uracil, 34. Carnitine, 35. Methionine, 36. Ethanolamine, 37. Choline, 38. 
myo-Inosito, 39. Betaine, and 40. Theophylline.
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FIGURE 3 - Fold change plots color-coded with p-values adjusted by Benjamini Hochberg method indicating the significance 
of altered metabolites in the liver of (A), XAP vs. control (B), model vs. control (C), and lung of XAP vs. control (D), model vs. 
control. The blue and red dashed lines represented variations of 20% and 100%, respectively. 
TABLE III - Different level of metabolites: In liver the level of the metabolites, alanine, succinate, glutamate, lactose and fumarate 
were aberrated significantly. Alanine (Leij-Halfwerk et al., 2000; Tessem et al., 2008), succinate (Yang, Pollard, 2013), glutamate 
(Fazzari et al., 2015; Willard, Koochekpour, 2013) are related to the cancer progression. Conversely, lactose (Goodman et al., 
2002) and fumarate play a pivotal role in the inhibition of cancer progression. However, in kidney, the level of succinate and lactate 
(Bonuccelli et al., 2010)were notably reduced, besides this the level of 3-Hydroxybutyrate (Bonuccelli et al.,2010) was augmented 
remarkably, which takes part a major role in tumor progression
Metabolites Expression Role in Cancer Action Reference
Alanine Down Progression
Elevated level of alanine is the cause of 
gluconeogenesis leads to lung cancer with 
weight loss, alanine is the major source of 
respiratory energy in cancer.
51, 52
Succinate Down Progression
Elevated cytosolic succinate inhibits HIFprolyl 
hydroxylase (PHD) and thereby Hypoxia-
inducible factor- α (HIF-α) hydroxylation.
53
Lactate Down Progression Initiation of angiogenesis 57
3-Hydroxybutyrate Down Progression Tumor progression 57
Glutamate Down Progression Induces migration, invasion and inhibition of apoptosis. 54, 55
Lactose Up Inhibition Reduce risk of ovarian cancer. 56
Fumarate Up Inhibition
Depletion of the level of fumarate links to 
accumulation of succinate, leads to activation of 
HIF-1α.
…..
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succinate can reflect the growth of cancer cells in vivo. 
After a consecutive 3 weeks oral MTE administration, 
the level of succinate was significantly lowered and back 
to normal. In another way, MTE was proved to exhibit 
antitumor action in vivo.
Here we used xenograft mice model for this study 
because all mammalian cells have similar biological 
pathways to regulate growth, differentiation, replication, 
and death. It has been also observed that Mice and Human 
have similar metabolic homogeneity and physiology 
disease pathogenesis. Additionally, mice acquire 
mutations by the equivalent spectrum of tumor suppressor 
genes and proto-oncogenes as Human (Balmain, Harris, 
2000) (Demetrius, 2005). So, this research outcome also 
will be effective on Human as well.
CONCLUSION
It has been revealed through 1H NMR-based 
metabolomics approach that MTE modulates the alteration 
of crucial metabolites, mainly succinate and lactate, which 
contribute major role in cancer formation.
FIGURE 4 - A schematic model that summarizes the role of 
succinate in the mitochondrion-to-cytosol signaling pathway. 
Succinate accumulated in the mitochondria due to SDH 
inhibition is transported to the cytosol. Elevated cytosolic 
succinate inhibits PHD and thereby HIF-α hydroxylation. 
Consequently, pVHL binding to HIF-α is decreased, and 
elevated HIF activity induces expression of genes that facilitate 
angiogenesis, metastasis, and metabolism, leading to more 
aggressive tumors (Table I).
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